美国 - 英文 - NLM (National Library of Medicine)

general injectables and vaccines, inc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 4 mg in 1 ml - a. by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). 2. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. synovitis of osteoarthritis. rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). acute and subacute bursitis. epicondylitis. acute nonspecific tenosynovitis. acute gouty arthritis. psoriatic arthritis. ankylosing spondylitis. 3. collagen diseases: during an exacerbation or as maintenance therapy in selected cases of : systemic lupus erythematosus. acute rheumatic carditis. 4. dermatologic diseases: pemphigus. se

美国 - 英文 - NLM (National Library of Medicine)

mylan institutional llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 4 mg in 1 ml - a. by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. 2. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode o

美国 - 英文 - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 10 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplas

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 10 mg in 1 ml - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. synovitis of osteoarthritis. rheumatoid arthritis, including juvenile

美国 - 英文 - NLM (National Library of Medicine)

rebel distributors corp - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 1 mg in 1 ml - for the treatment of the following conditions: ophthalmic: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. otic: steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. funga

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 1 mg in 1 ml - for the treatment of the following conditions: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. fungal diseas

美国 - 英文 - NLM (National Library of Medicine)

medical purchasing solutions, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 10 mg in 1 ml - a. by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. 2. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an ac

肯尼亚 - 英文 - Pharmacy and Poisons Board

dexamethasone sod.phosphate 4mg/1ml inj 10's - injection - dexamethasone sod.phosphate 4mg/1ml inj 10's 4mg - dexamethasone

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexamethasone 0.5mg - tablet - 0.5 mg - active: dexamethasone 0.5mg excipient: lactose monohydrate magnesium stearate povidone wheat starch - dexamethasone is indicated for replacement therapy in secondary adrenal insufficiency arising from insufficient corticotrophin secretion. it is not indicated for primary adrenal insufficiency states, such as addisons disease or after adrenalectomy. in such cases hydrocortisone and fludrocortisone in combination is more appropriate. dexamethasone is also indicated for allergic disorders such as bronchial asthma and allergic skin reactions, blood disorders such as leukaemia, thrombocytopoenia and haemolytic anaemias, selected collagen and rheumatic disorders (only rarely in rheumatoid arthritis), gastrointestinal disorders such as inflammatory bowel disease, connective tissue disorders such as arteritis, systemic lupus erythematosus (but not scleroderma), some skin diseases such as pemphigus, oedema, some eye disorders, certain neoplastic disorders such as cerebral neoplasm, secondary hypercalcaemia, and acute leukaemia in children. it may also be used to prevent neonatal respiratory distress syndrome and in the diagnosis of cushing's syndrome. dexamethasone is indicated in the treatment of coronavirus disease 2019 (covid-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexamethasone 4mg - tablet - 4 mg - active: dexamethasone 4mg excipient: lactose monohydrate magnesium stearate maize starch povidone - dexamethasone is indicated for replacement therapy in secondary adrenal insufficiency arising from insufficient corticotrophin secretion. it is not indicated for primary adrenal insufficiency states, such as addisons disease or after adrenalectomy. in such cases hydrocortisone and fludrocortisone in combination is more appropriate. dexamethasone is also indicated for allergic disorders such as bronchial asthma and allergic skin reactions, blood disorders such as leukaemia, thrombocytopoenia and haemolytic anaemias, selected collagen and rheumatic disorders (only rarely in rheumatoid arthritis), gastrointestinal disorders such as inflammatory bowel disease, connective tissue disorders such as arteritis, systemic lupus erythematosus (but not scleroderma), some skin diseases such as pemphigus, oedema, some eye disorders, certain neoplastic disorders such as cerebral neoplasm, secondary hypercalcaemia, and acute leukaemia in children. it may also be used to prevent neonatal respiratory distress syndrome and in the diagnosis of cushing's syndrome. dexamethasone is indicated in the treatment of coronavirus disease 2019 (covid-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.